Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a sell rating in a research report report published on Saturday morning.

Several other equities analysts have also recently weighed in on RVPH. Chardan Capital reissued a “buy” rating and set a $40.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Reviva Pharmaceuticals Trading Down 6.8%

Reviva Pharmaceuticals stock opened at $2.47 on Friday. The business’s fifty day simple moving average is $5.40 and its two-hundred day simple moving average is $8.47. Reviva Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $23.40. The company has a market capitalization of $14.42 million, a price-to-earnings ratio of -0.27 and a beta of 0.10.

Institutional Trading of Reviva Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the period. NewEdge Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 1st quarter valued at approximately $58,000. XTX Topco Ltd increased its holdings in Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after acquiring an additional 63,893 shares in the last quarter. Lido Advisors LLC purchased a new stake in Reviva Pharmaceuticals in the 3rd quarter worth approximately $37,000. Finally, Millennium Management LLC raised its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the period. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.